Kamada at Wainwright: A Dead Pipeline Bet Leaves Behind a Cheap, Cash-Generative Compounder

A slot on an investor-conference agenda is usually the least newsworthy thing a company can announce — management files to New York, replays the same slide deck, and nothing changes. For Kamada (KMDA), the seat at H.C. Wainwright's 28th annual conference, running September 14-16 in Manhattan, is the rare exception worth a few minutes. Not because the presentation itself moves the stock, but because the story the executives will tell is no longer the one that defined this company for a decade.

Kamada is a small, vertically integrated specialty-pharma company that turns donated plasma into protein therapies for rare and acute conditions — rabies (KEDRAB), chickenpox (VARIZIG), immune globulins such as WINRHO and CYTOGAM, and hepatitis products — alongside a distribution business in Israel. For years, the investment case was not this commercial line but a speculative pipeline bet: an inhaled version of alpha-1 antitrypsin to treat a rare genetic lung disease, tested in a global Phase 3 study.

That bet ended badly. In December 2025, Kamada discontinued the Phase 3 InnovAATe trial after an interim futility analysis concluded it was unlikely to meet its primary lung-function endpoint. For a stock that had long been part orphan-drug lottery ticket, this was the moment the equity had to be judged on what was left — the actual business. The shift from hoping about a drug to measuring a company is precisely what the presentation gives an investor an excuse to do.

The commercial engine is doing all the talking now

The business that remained has turned out to be a genuinely compounding one. Second-quarter 2026 revenue rose 23% year over year to $54.9 million, powered mainly by U.S. sales of KEDRAB along with VARIZIG and HEPAGAM, and adjusted EBITDA grew 29% to $14.1 million on a 26% margin. That was enough to push first-half revenue to a record $100.2 million, up 13%, with adjusted EBITDA of $25.7 million and net income of $13.4 million, up 18%.

The step-change versus a year ago is worth pausing on, because it explains the price action. Kamada's 2025 full year produced $180.5 million of revenue (up 12%), $42 million of adjusted EBITDA (up 23%) and $20.2 million of net income (up 40%) — solid, but a base the market largely ignored while the pipeline question hung over it. Now that the pipeline is gone, management reaffirmed 2026 guidance for $200-205 million of revenue and $50-53 million of adjusted EBITDA, roughly 13% and 23% growth. First half already printed about half the midpoint.

There is also new, concrete demand to point at on stage. Kamada signed a first-time three-year agreement to supply about $50 million of plasma to a leading biopharmaceutical company, with initial sales expected in the fourth quarter — and says that amount is already baked into the 2026 guidance, not upside. Distribution growth from launching biosimilars in Israel and expanding into the MENA region adds a second, lower-margin engine.

The multiple already prices the outcome — and may underprice the growth

Here is where the risk-reward deserves the valuation lens it rarely gets. At roughly $8.21, Kamada trades at about $474 million in market cap and an enterprise value near $404 million, with roughly $70 million in cash and short-term investments and no meaningful net debt. Against trailing adjusted EBITDA that is about 9.4 times EV/EBITDA — and around 7.8 times on this year's guided midpoint. Earnings run about 21 times trailing, roughly 13% growth. For a company compounding revenue double digits with expanding cash flow and net cash on the balance sheet, that is a modest multiple, not an expensive one.

The fair caveat: Kamada is not Grifols-adjacent cheap by accident. As a plasma player it carries concentration risk — a handful of products, several (KEDRAB, VARIZIG) in competitive or tendered markets — and its growth is partly arriving through lower-margin channels. Gross margin fell to 42% in the first half from 45% a year earlier as mix shifted toward distribution and KEDRAB. The company is effectively a small-cap cash compounder, not a high-margin software story, and the valuation correctly treats it that way.

The 5% headline yield flatters — read the dividend correctly

The dividend is a genuine part of the case, but it deserves a careful read. The trailing-12-month yield of about 5% looks generous, yet that number includes a one-time $0.20 special dividend declared in early 2025. The go-forward policy Kamada adopted is an annual cash dividend of $0.25 per share, which at today's price is closer to a 3% yield.

More important than the percentage is whether the balance sheet can honor it through the cycle. It can, for now: the $0.25 payment (roughly $14.4 million) compares against first-half operating cash flow of $17.8 million, and the ~$70 million cash cushion absorbs the lumpiness. But the payout is a large share of free cash flow, and it will be the first thing tested if the plasma deal or core product demand stumbles. That is not a reason to avoid the stock; it is a reason not to buy solely for the yield.

What the conference can and cannot tell you

The value of a corporate presentation here is narrow but real. It will not add new facts — this is the same commercial story, the same guidance, the same mid-September date that H.C. Wainwright hosts every year. What it does is widen the audience for a micro-cap that fewer than a handful of analysts cover, and it re-states the proof window that actually matters. Over the next two to four quarters the falsifiable claims are: that Q4 plasma revenues actually begin, that KEDRAB and VARIZIG demand holds so the second half delivers the implied step-up, and that the gross-margin drift stabilizes.

The honest read-through is that Kamada is a decent cash-compounding business selling at a fair-to-cheap multiple with a real, if newly burdened, dividend — and that the bear case lives in its dependence on a few products and the payout ratio, not in any story the deck can fix. For a holder or a watcher, the encouraging part is that the stock no longer needs the pipeline to work: the base business self-funds, grows double digits, and trades around nine times EBITDA. What would change that view is precisely what the next two quarters will reveal — whether the cash and the guidance convert to the record results management is pointing at.